scholarly journals SARS-CoV-2 in Urine May Predict a Severe Evolution of COVID-19

2021 ◽  
Vol 10 (18) ◽  
pp. 4061
Author(s):  
Alessandro Perrella ◽  
Mario Brita ◽  
Francesco Coletta ◽  
Simona Cotena ◽  
GiamPaola De Marco ◽  
...  
Keyword(s):  
Intensive Care ◽  
Respiratory Tract ◽  
Intensive Care Units ◽  
Disease Severity ◽  
Death Rate ◽  
Severe Disease ◽  
Serum Levels ◽  
C Reactive Protein ◽  
Disease Evolution ◽  
Reactive Protein

We hypothesized that the spread of SARS-CoV-2 in urine during a severe COVID-19 infection may be the expression of the worsening disease evolution. Therefore, the aim of this study was to verify if the COVID-19 disease severity is related to the viral presence in urine samples. We evaluated the clinical evolution in acute COVID-19 patients admitted in the sub-intensive care and intensive care units between 28 of December 2020 and 15th of February 2021 and being positive for SARS-CoV-2 RNA in the respiratory tract, including repeated endotracheal aspirates (ETA), sputum, nasopharyngeal swabs (NPS) and urine. We found that those subjects with SARS-COV-2 in the urine at admittance (8 out of 60 eligible patients) had a more severe disease than those with negative SARS-CoV-2 in urine. Further, they showed an increase in fibrinogen and (C-reactive Protein) CRP serum levels, requiring mechanic ventilation. Of those with positive SARS-CoV-2 in the urine, 50% died. According to our preliminary results, it seems that the presence of SARS-CoV-2 in the urine characterizes patients with a more severe disease and is also related to a higher death rate.

scholarly journals Serum C-Reactive Protein and Interleukin-6 Levels as Biomarkers for Disease Severity and Clinical Outcomes in Patients with Idiopathic Granulomatous Mastitis

2021 ◽  
Vol 10 (10) ◽  
pp. 2077
Author(s):  
Yi-Min Huang ◽  
Chiao Lo ◽  
Chiao-Feng Cheng ◽  
Cheng-Hsun Lu ◽  
Song-Chou Hsieh ◽  
...  
Keyword(s):  
Disease Severity ◽  
Severe Disease ◽  
Linear Regression Analysis ◽  
Multiple Linear Regression Analysis ◽  
Serum Biomarkers ◽  
Healthy Controls ◽  
Granulomatous Mastitis ◽  
C Reactive Protein ◽  
Idiopathic Granulomatous Mastitis ◽  
Reactive Protein

Idiopathic granulomatous mastitis (IGM) is a rare inflammatory breast disease mimicking breast cancer. Limited research has been conducted on the application of serum biomarkers. This study aims to investigate the association of serum biomarkers with disease severity in patients with IGM. From November 2011 to March 2020, medical records of patients with IGM were reviewed. Serum cytokine levels were measured in patients and healthy controls between July 2018 and March 2020. A total of 41 patients with histologically proven IGM were found. Serum interleukin (IL)-6 level was significantly higher in patients with IGM (n = 11) than healthy controls (n = 7). Serum IL-6 and C-reactive protein (CRP) levels were significantly higher in patients with severe disease than mild and moderate disease. Serum IL-6 (Spearman’s ρ = 0.855; p < 0.001) and CRP (Spearman’s ρ = 0.838; p = 0.001) levels were associated with time to resolution. A higher serum CRP level was associated with a longer time to resolution (B = 0.322; p < 0.001) in multiple linear regression analysis. Serum IL-6 and CRP levels can be used as biomarkers for the evaluation of disease severity in IGM. IL-6 may play a crucial role in the immunopathology of IGM.

scholarly journals 446. Prognostic Value of Absolute Lymphocyte Count for Disease Severity and Clinical Outcomes in Adult COVID-19 Inpatients

2021 ◽  
Vol 8 (Supplement_1) ◽  
pp. S324-S324
Author(s):  
Jianli Niu ◽  
Candice Sareli ◽  
Maria Deane ◽  
Aharon E Sareli
Keyword(s):  
Lactate Dehydrogenase ◽  
Clinical Outcomes ◽  
Disease Severity ◽  
Interleukin 6 ◽  
Lymphocyte Count ◽  
Absolute Lymphocyte Count ◽  
Serum Levels ◽  
C Reactive Protein ◽  
Icu Admission ◽  
Reactive Protein

Abstract Background Lymphopenia has been reported as a relatively frequent finding in patients with coronavirus disease 2019 (COVID-19). This study aimed to assess the use of absolute lymphocyte count (ALC) as a prognostic biomarker for disease severity and clinical outcomes. Methods A cohort of adult patients with COVID-19 admitted to Memorial Healthcare System, Hollywood, Florida from March 7, 2020 to January 18, 2021 was retrospectively analyzed. An absolute lymphocyte count (ALC) &lt; 1.1 × 109/L was used as cutoff point to define lymphopenia. Correlations of ALC upon admission with age and serum levels of C-reactive protein, interleukin-6, lactate dehydrogenase, and creatinine were analyzed. Univariate and multivariate regression models were developed to assess the association of lymphopenia with the risk of ICU admission and clinical outcomes. Results 4,485 hospitalized patients were included in the final analyses. Median age was 61 (interquartile range, 47-73) years and 2,311 (51.5%) were men. Lymphopenia was more frequent in patients admitted to the ICU compared to those that were not admitted to the ICU, with an odds ratio of 2.14 (95% confidence interval [CI], 1.78-2.56, p &lt; .0001) (Figure 1). The actual value of the ALC was negatively correlated with age and serum levels of C-reactive protein, interleukin-6, lactate dehydrogenase, and creatinine (all p &lt; 0.005). Patients with lymphopenia (n=2,409) compared to those without lymphopenia (n=2,076) had multivariable-adjusted odds ratios of 1.85 (95% CI, 1.53-2.24) for ICU admission, 2.08 (95% CI, 1.67-2.58) for intubation, 1.98 (95% CI, 1.31-3.00) for development of acute kidney failure, and 2.23 (95% CI, 1.79-2.79) for in-hospital mortality (Table 1). Analyses were adjusted for age, gender, race, hypertension, diabetes, chronic obstructive pulmonary disease, chronic kidney disease, coronary artery disease, malignancy, obesity, and smoking. Conclusion Lymphopenia in adult COVID -19 hospitalized patients was associated with increased risk of disease severity (as evidenced by need for ICU admission) and poor clinical outcomes. Absolute lymphocyte count may help with prognostication in individuals hospitalized with COVID-19. Disclosures All Authors: No reported disclosures

scholarly journals Proadrenomedullin Predicts Severe Disease in Children with Suspected Community-Acquired Pneumonia

2020 ◽  
Author(s):  
Todd A Florin ◽  
Lilliam Ambroggio ◽  
Cole Brokamp ◽  
Yin Zhang ◽  
Eric S Nylen ◽  
...  
Keyword(s):  
Disease Severity ◽  
Odds Ratio ◽  
Severe Disease ◽  
Antibiotic Use ◽  
Supplemental Oxygen ◽  
Community Acquired Pneumonia ◽  
C Reactive Protein ◽  
Chest Drainage ◽  
Reactive Protein ◽  
Complicated Pneumonia

Abstract Background Proadrenomedullin (proADM), a vasodilatory peptide with antimicrobial and anti-inflammatory properties, predicts severe outcomes in adults with community-acquired pneumonia (CAP) to a greater degree than C-reactive protein and procalcitonin. We evaluated the ability of proADM to predict disease severity across a range of clinical outcomes in children with suspected CAP. Methods We performed a prospective cohort study of children 3 months to 18 years with CAP in the emergency department (ED). Disease severity was defined as: mild (discharged home), mild-moderate (hospitalized but not moderate-severe or severe), moderate-severe (e.g., hospitalized with supplemental oxygen, broadening of antibiotics, complicated pneumonia), and severe (e.g., vasoactive infusions, chest drainage, severe sepsis). Outcomes were examined using proportional odds logistic regression within the cohort with suspected CAP and in a subset with radiographic CAP. Results Among 369 children, median proADM increased with disease severity [mild: median 0.53 nmol/L (IQR:0.43, 0.73), mild-moderate: 0.56 nmol/L (IQR:0.45, 0.71), moderate-severe: 0.61 nmol/L (IQR:0.47, 0.77), severe: 0.70 nmol/L (IQR:0.55, 1.04) (p=.002)]. ProADM was significantly associated with increased odds of developing severe outcomes (suspected CAP odds ratio (OR) 1.68 [95% CI, 1.2, 2.36], radiographic CAP OR 2.11 [95% CI, 1.36, 3.38]) adjusted for age, fever duration, antibiotic use, and pathogen. ProADM had an area under the ROC curve (AUC) of 0.64 (95%CI, 0.56,0.72) in those with suspected CAP and AUC 0.77 (95% CI, 0.68,0.87) in radiographic CAP. Conclusions ProADM was associated with severe disease and discriminated moderately well children who developed severe disease from those who did not, particularly in radiographic CAP.

scholarly journals Gut microbiota diversity and C-Reactive Protein are predictors of disease severity in COVID-19 patients

2021 ◽  
Author(s):  
André Moreira-Rosário ◽  
Cláudia Marques ◽  
Hélder Pinheiro ◽  
João Ricardo Araújo ◽  
Pedro Ribeiro ◽  
...  
Keyword(s):  
Risk Factors ◽  
Gut Microbiota ◽  
Disease Severity ◽  
Severe Disease ◽  
Clinical Severity ◽  
Rrna Gene ◽  
C Reactive Protein ◽  
Clinical Progression ◽  
Reactive Protein ◽  
Microbiota Diversity

AbstractRisk factors for COVID-19 disease severity are still poorly understood. Considering the pivotal role of gut microbiota on host immune and inflammatory functions, we investigated the association between changes in gut microbiota composition and the clinical severity of COVID-19. We conducted a multicentre cross-sectional study prospectively enrolling 115 COVID-19 patients categorized according to: 1) WHO Clinical Progression Scale - mild 19 (16.5%), moderate 37 (32.2%) or severe 59 (51.3%); and 2) location of recovery from COVID-19 - ambulatory 14 (household isolation; 12.2%), hospitalized in ward 40 (34.8%) or intensive care unit 61 (53.0%). Gut microbiota analysis was performed through 16S rRNA gene sequencing and data obtained was further related with clinical parameters of COVID-19 patients. Risk factors for COVID-19 severity were identified by univariate and multivariable logistic regression models.In comparison with mild COVID-19 patients, the gut microbiota of moderate and severe patients has: a) lower Firmicutes/Bacteroidetes ratio, b) higher abundance of Proteobacteria; and c) lower abundance of beneficial butyrate-producing bacteria such as Roseburia and Lachnospira genera. Multivariable regression analysis showed that Shannon index diversity (odds ratio [OR] 2.85 [95% CI 1.09-7.41]; p=0.032) and C-Reactive Protein (OR 3.45 [95% CI 1.33-8.91]; p=0.011) were risk factors for COVID-19 severe disease (a score of 6 or higher in WHO clinical progression scale).In conclusion, our results demonstrated that hospitalised moderate and severe COVID-19 patients have microbial signatures of gut dysbiosis and for the first time, the gut microbiota diversity is pointed out as a prognostic biomarker for COVID-19 disease severity.

scholarly journals CORRELATION BETWEEN SERUM C-REACTIVE PROTEIN LEVEL WITH SEVERITY OF THE DISEASE IN COVID-19 PATIENTS

2021 ◽  
Vol 5 (11) ◽  
Author(s):  
Sangeeta Gahlot ◽  
Surendra Yadav ◽  
Makkhan Lal Saini
Keyword(s):  
Severe Disease ◽  
Serum Levels ◽  
Cross Sectional Study ◽  
P Value ◽  
C Reactive Protein ◽  
Cross Sectional ◽  
Reactive Protein ◽  
Group I ◽  
Moderate Disease ◽  
Severity Of The Disease

Background: To find the levels of serum CRP in confirmed Covid-19 patients and to compare their levels in patients with mild to moderate disease and patients with severe disease who required ICU care for management. Methods: A Cross sectional study was carried out on 100 confirmed cases of Covid-19, in whom Serum levels of Random sugar (RBS), Creatinine, Urea, C- reactive protein (CRP) were measured. Results: The levels of serum Urea, Creatinine were significantly increased in group II when compared to group 1, and the levels of CRP were significantly increased with p value <0.0001 in group IIwhen compared to group I. Conclusion: Findings of our study suggest that determination of biochemical parameters like CRP at the time of hospitalization helps in predicting the severity of disease and need for ICU for better treatment management and prevention of adverse outcome. Keywords: Severe acute respiratory syndrome, Covid-19, C- reactive protein, Intensive care unit.

scholarly journals C-Reactive Protein or Procalcitonin Combined with Rhinorrhea for Discrimination of Viral from Bacterial Infection in Hospitalized Adults of Non-Intensive Care Medical with Lower Respiratory Tract Infection

2021 ◽  
Author(s):  
DUAN Shengchen ◽  
Xiaoying Gu ◽  
Guohui Fan ◽  
Fei Zhou ◽  
Guangfa Zhu ◽  
...  
Keyword(s):  
Intensive Care ◽  
Tract Infection ◽  
Respiratory Tract ◽  
Bacterial Infection ◽  
Respiratory Tract Infection ◽  
Lower Respiratory Tract Infection ◽  
Lower Respiratory Tract ◽  
Clinical Characteristics ◽  
C Reactive Protein ◽  
Reactive Protein

Abstract Background: Whether procalcitonin (PCT) or C-reactive protein (CRP) combined with some clinical characteristics can better distinguish viral from bacterial infection is not clear. The aim was to assess the ability of PCT or CRP combined with clinical characteristics to distinguish between viral and bacterial infections in hospitalized non-intensive care unit (ICU) adults with lower respiratory tract infection (LRTI).Methods: This was a post-hoc analysis of a randomized clinical trial previously conducted among LRTI patients. The ability of PCT, CRP, and PCT or CRP combined with clinical characteristics to discriminate between viral and bacterial infection were estimated by portraying receiver operating characteristic (ROC) curves among patients with only vial or typical bacterial infection .Results: In total, 209 patients (virus 69%, bacteria 31%) were included in this study. When using CRP or PCT to discriminate between viral and bacterial LRTI, the optimal cut-off point were 22mg/L and 0.18ng/ml, respectively. When the optimal cut-off for CRP (≤22ml/L) or PCT (≤0.18ng/ml) combined with rhinorrhea was used to discriminate viral from bacterial LRTI, the AUCs were 0.81 (95% CI, 0.75–0.87) and 0.80 (95% CI, 0.74–0.86), respectively. When CRP≤22ml/L, PCT≤0.18ng/ml and rhinorrhea were combined, the AUC was 0.86 (95% CI, 0.80–0.91), which was statistically significant higher than that when CRP(≤22mg/L) or PCT (≤0.18ng/mL) was combined with rhinorrhea (p=0.0107 and p=0.0205).Conclusions: Either CRP≤22mg/L or PCT≤0.18ng/mL combined with rhinorrhea could help distinguish viral from bacterial infection in hospitalized non-ICU adults with LRTI. When rhinorrhea was combined together, discrimination ability can be further improved.

Sign in / Sign up

Export Citation Format

Share Document